What Prediction Markets Are Forecasting

Prediction markets currently give about a 6% chance that the world will see a full calendar year with zero reported cases of wild poliovirus before 2030. In simpler terms, traders see this outcome as very unlikely, estimating the odds at roughly 1 in 16. This low probability suggests that, while global eradication efforts continue, the collective intelligence of the market is skeptical about completely interrupting transmission in the next six years.

Why the Market Sees It This Way

The low confidence stems from persistent challenges in the final stages of eradication. Wild polio is now endemic in only two countries, Afghanistan and Pakistan, but eliminating the last cases is notoriously difficult. These remaining pockets face significant barriers, including security issues that hinder vaccination campaigns, vaccine hesitancy, and complex logistics.

A major complicating factor is the rise of vaccine-derived polio. In areas with low immunization rates, the weakened virus from the oral vaccine can circulate and regain strength, causing outbreaks. These cases are not counted as "wild" polio for this specific market, but their occurrence signals weak health systems and makes the goal of zero wild cases harder to achieve. Historical context also plays a role. The original goal for eradication was the year 2000, and repeated deadlines have been missed, making markets cautious about new timelines.

Key Dates and Events to Watch

The timeline is continuous, but watch for annual case reports from the Global Polio Eradication Initiative. A sustained drop to zero cases in Afghanistan and Pakistan for multiple months would be a strong signal.

Key moments include the outcomes of national immunization days in both countries, which are critical for reaching every child. Any major political or security shift that improves humanitarian access in endemic regions could change the forecast. Conversely, a new large outbreak of wild polio, even if contained quickly, would likely push predictions toward "No."

How Reliable Are These Predictions?

Prediction markets often do well at aggregating expert knowledge on technical, long-term questions like this one, where many specialists are closely tracking the data. However, their accuracy can be limited by low trading volume, as seen here with a niche following. For disease eradication, forecasts can be swayed by unexpected breakthroughs or setbacks that are hard to price in years in advance. While the market's current skepticism aligns with many public health analyses, its low probability should be seen as a snapshot of informed doubt, not a final verdict.